CACNA1D and Parkinson disease: We therefore conducted whole-cell voltage-clamp experiments to quantify sclareol potency for Cav1.3 and its selectivity toward Cav1.2 and Cav2.3, another channel subtype potentially involved in PD pathophysiology [12].